Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III ...
After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...
RAS proteins, their regulators and the downstream enzymes that they control are activated in many tumour types by a variety of mechanisms, including oncogenic mutation of RAS genes. They are crucial ...
Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. The glycolysis ...
REST v1 random summary GET /{lang}.wikipedia.org/api/rest_v1/page/random/summary Fetch a random article REST v1 summary by title GET /{lang}.wikipedia.org/api/rest_v1 ...
The 2026 Pathways Research Explorers online application is now open. Please use the link to Apply Now! Applications close 11:59 pm PST March 6, 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results